S&P 500   3,298.46 (+1.60%)
DOW   27,173.96 (+1.34%)
QQQ   271.56 (+2.32%)
AAPL   112.28 (+3.75%)
MSFT   207.82 (+2.28%)
FB   254.82 (+2.12%)
GOOGL   1,439.06 (+1.14%)
AMZN   3,095.13 (+2.49%)
TSLA   407.34 (+5.04%)
NVDA   514.95 (+4.26%)
BABA   271.09 (+0.50%)
CGC   14.17 (-0.70%)
GE   6.11 (+0.99%)
MU   49.14 (-0.67%)
AMD   78.06 (+2.95%)
T   28.04 (+0.00%)
F   6.51 (-2.25%)
ACB   5.05 (-2.88%)
GILD   62.25 (+0.00%)
NFLX   482.88 (+2.07%)
DIS   124.00 (+1.23%)
BAC   23.49 (+0.64%)
BA   156.03 (+6.83%)
S&P 500   3,298.46 (+1.60%)
DOW   27,173.96 (+1.34%)
QQQ   271.56 (+2.32%)
AAPL   112.28 (+3.75%)
MSFT   207.82 (+2.28%)
FB   254.82 (+2.12%)
GOOGL   1,439.06 (+1.14%)
AMZN   3,095.13 (+2.49%)
TSLA   407.34 (+5.04%)
NVDA   514.95 (+4.26%)
BABA   271.09 (+0.50%)
CGC   14.17 (-0.70%)
GE   6.11 (+0.99%)
MU   49.14 (-0.67%)
AMD   78.06 (+2.95%)
T   28.04 (+0.00%)
F   6.51 (-2.25%)
ACB   5.05 (-2.88%)
GILD   62.25 (+0.00%)
NFLX   482.88 (+2.07%)
DIS   124.00 (+1.23%)
BAC   23.49 (+0.64%)
BA   156.03 (+6.83%)
S&P 500   3,298.46 (+1.60%)
DOW   27,173.96 (+1.34%)
QQQ   271.56 (+2.32%)
AAPL   112.28 (+3.75%)
MSFT   207.82 (+2.28%)
FB   254.82 (+2.12%)
GOOGL   1,439.06 (+1.14%)
AMZN   3,095.13 (+2.49%)
TSLA   407.34 (+5.04%)
NVDA   514.95 (+4.26%)
BABA   271.09 (+0.50%)
CGC   14.17 (-0.70%)
GE   6.11 (+0.99%)
MU   49.14 (-0.67%)
AMD   78.06 (+2.95%)
T   28.04 (+0.00%)
F   6.51 (-2.25%)
ACB   5.05 (-2.88%)
GILD   62.25 (+0.00%)
NFLX   482.88 (+2.07%)
DIS   124.00 (+1.23%)
BAC   23.49 (+0.64%)
BA   156.03 (+6.83%)
S&P 500   3,298.46 (+1.60%)
DOW   27,173.96 (+1.34%)
QQQ   271.56 (+2.32%)
AAPL   112.28 (+3.75%)
MSFT   207.82 (+2.28%)
FB   254.82 (+2.12%)
GOOGL   1,439.06 (+1.14%)
AMZN   3,095.13 (+2.49%)
TSLA   407.34 (+5.04%)
NVDA   514.95 (+4.26%)
BABA   271.09 (+0.50%)
CGC   14.17 (-0.70%)
GE   6.11 (+0.99%)
MU   49.14 (-0.67%)
AMD   78.06 (+2.95%)
T   28.04 (+0.00%)
F   6.51 (-2.25%)
ACB   5.05 (-2.88%)
GILD   62.25 (+0.00%)
NFLX   482.88 (+2.07%)
DIS   124.00 (+1.23%)
BAC   23.49 (+0.64%)
BA   156.03 (+6.83%)
Log in
NASDAQ:ELGX

Endologix Stock Forecast, Price & News

$0.03
-0.01 (-23.81 %)
(As of 09/24/2020 12:00 AM ET)
Add
Compare
Today's Range
$0.03
Now: $0.03
$0.04
50-Day Range
$0.04
MA: $0.07
$0.22
52-Week Range
$0.22
Now: $0.03
$7.10
Volume219,560 shs
Average Volume1.28 million shs
Market Capitalization$613,504.00
P/E RatioN/A
Dividend YieldN/A
Beta0.73
Endologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. The company offers minimally-invasive endovascular aneurysm repair (EVAR), including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the Ovation abdominal stent graft system. It also provides endovascular aneurysm sealing system (EVAS) product that is based on the Nellix EVAS system to seal the aneurysm, and provides blood flow to the legs through two blood lumens. In addition, the company offers proximal aortic extensions and limb extensions, which allow physicians to customize the implant to fit the patient's anatomy; and accessories to facilitate the delivery of its EVAR and EVAS products, including compatible guidewires, inflation devices, and snares. It sells its products through direct sales force, and a network of third party distributors and agents. The company was formerly known as Radiance Medical Systems, Inc. and changed its name to Endologix, Inc. in May 2002. Endologix, Inc. was founded in 1992 and is headquartered in Irvine, California.
Read More
Endologix logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.55 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
Current SymbolNASDAQ:ELGX
CUSIP29266S10
Phone949-595-7200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$143.37 million
Book Value$3.56 per share

Profitability

Net Income$-64,760,000.00

Miscellaneous

Employees528
Market Cap$613,504.00
Next Earnings DateN/A
OptionableOptionable
$0.03
-0.01 (-23.81 %)
(As of 09/24/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ELGX News and Ratings via Email

Sign-up to receive the latest news and ratings for ELGX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Endologix (NASDAQ:ELGX) Frequently Asked Questions

How has Endologix's stock been impacted by COVID-19?

Endologix's stock was trading at $0.94 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ELGX stock has decreased by 96.6% and is now trading at $0.0320.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Endologix?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Endologix in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Endologix
.

How were Endologix's earnings last quarter?

Endologix, Inc. (NASDAQ:ELGX) issued its quarterly earnings results on Monday, May, 11th. The medical instruments supplier reported ($0.80) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.67) by $0.13. The medical instruments supplier had revenue of $28.51 million for the quarter, compared to the consensus estimate of $28.50 million. Endologix had a negative net margin of 44.65% and a negative return on equity of 63.96%.
View Endologix's earnings history
.

When did Endologix's stock split? How did Endologix's stock split work?

Endologix's stock reverse split on Wednesday, March 6th 2019. The 1-10 reverse split was announced on Tuesday, March 5th 2019. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, March 5th 2019. An investor that had 100 shares of Endologix stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for ELGX?

2 equities research analysts have issued 1 year price targets for Endologix's stock. Their forecasts range from $1.00 to $6.00. On average, they expect Endologix's stock price to reach $3.00 in the next twelve months. This suggests a possible upside of 9,275.0% from the stock's current price.
View analysts' price targets for Endologix
.

Who are some of Endologix's key competitors?

What other stocks do shareholders of Endologix own?

Who are Endologix's key executives?

Endologix's management team includes the following people:
  • Mr. John Onopchenko, CEO & Director (Age 60)
  • Mr. Vaseem Mahboob, Chief Financial Officer (Age 50)
  • Dr. Michael V. Chobotov, Chief Technology Officer (Age 58)
  • Mr. Jeffrey S. Brown, Chief Operations Officer
  • Mr. Jeremy B. Hayden, Gen. Counsel (Age 49)

What is Endologix's stock symbol?

Endologix trades on the NASDAQ under the ticker symbol "ELGX."

Who are Endologix's major shareholders?

Endologix's stock is owned by a number of institutional and retail investors. Top institutional investors include Western Standard LLC (1.28%). Company insiders that own Endologix stock include Gregory D Waller, John Onopchenko, Thomas F Zenty III, Thomas Wilder and Vaseem Mahboob.
View institutional ownership trends for Endologix
.

Which major investors are buying Endologix stock?

ELGX stock was acquired by a variety of institutional investors in the last quarter, including Western Standard LLC. Company insiders that have bought Endologix stock in the last two years include John Onopchenko, Thomas F Zenty III, and Vaseem Mahboob.
View insider buying and selling activity for Endologix
.

How do I buy shares of Endologix?

Shares of ELGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Endologix's stock price today?

One share of ELGX stock can currently be purchased for approximately $0.03.

How big of a company is Endologix?

Endologix has a market capitalization of $613,504.00 and generates $143.37 million in revenue each year. The medical instruments supplier earns $-64,760,000.00 in net income (profit) each year or ($2.19) on an earnings per share basis. Endologix employs 528 workers across the globe.

What is Endologix's official website?

The official website for Endologix is www.endologix.com.

How can I contact Endologix?

Endologix's mailing address is 2 MUSICK, IRVINE CA, 92618. The medical instruments supplier can be reached via phone at 949-595-7200 or via email at [email protected]

This page was last updated on 9/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.